Conatus Pharmaceuticals (CNAT) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Conatus Pharmaceuticals Reports 2015 Financial Results and Program Updates
March 9, 2016 4:05 PM ESTSAN DIEGO, March 09, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq: CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the fourth quarter and full year ended December 31, 2015, and provided updates on its clinical development programs.
Financial ResultsThe net loss for the fourth quarter of 2015 was $6.0 million compared with $5.3 million for the fourth quarter of 2014. The net loss for the full year 2015 was $24.1 million compared with $22.3 million for the full year 2014.
Research and development expenses... More
